NEW YORK (GenomeWeb News) — Agilent Technologies has licensed labeling technology from Kreatech for use with its formalin-fixed paraffin-embedded DNA tissue-extraction method, Agilent said today.
Agilent said it will use Kreatech’s Universal Linkage System, which is a non-enzymatic direct-labeling methodology that has been optimized to be used with Agilent’s oligo comparative genomic hybridization microarrays.
There are around 400 million FFPE-preserved DNA samples in tissue banks that are “too degraded to use in microarray analysis techniques such as aCGH,” the company said.
Having the capability to access degraded FFPE samples for microarray use offers “tremendous promise for cancer researchers,” Jay Kaufman, Agilent’s marketing director, said in a statement.
Financial terms of the agreement were not released.